ArticleThe oncologist2020

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study.

Karen Julien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.